New partnership with Dermagnostix

We are delighted to be working with Dermagnostix, based in Freiburg im Breisgau. Our distribution partnership with the German company will start on 1 September 2025.

Dermagnostix was founded as a spin-off of the Hahn-Schickard Institute in Freiburg, the Helmholtz Centre Munich (HMGU), and the Technical University of Munich. The company specialises in developing molecular diagnostic tests for dermatological issues, having launched the first such test for the differential diagnosis of psoriasis and eczema.

“We are excited about our new partnership with Dermagnostix in Austria, Switzerland, Slovenia, Croatia, the Czech Republic, Slovakia, and Poland,” says Didier Saulnier, Deputy Head of the Molecular Diagnostics Business Unit at Axonlab. “Dermagnostix's innovative LabDisk technology is an ideal addition to our portfolio and represents a new era in dermatological molecular diagnostics. In particular, its unique ability to differentiate between psoriasis and eczema demonstrates the potential of state-of-the-art analytics to improve patient care by making it more accurate and faster.”

Psoriasis and eczema are among the most common chronic inflammatory skin diseases and are often difficult to distinguish from each other clinically and histopathologically. At the same time, correct diagnosis is becoming increasingly important in terms of treatment, given the numerous specific biologics and small molecules available. PsorX-LabDisk extends the diagnosis of psoriasis and eczema to the molecular level.

Axonlab has successfully established itself in numerous European markets over the past 35 years, building up a strong and steadily growing customer network in the process. Thanks to our many years of experience, close partnerships with customers and service-oriented approach, we can provide Dermagnostix with the optimal support it needs to realise its full potential. Together, we can ensure that this innovation benefits as many laboratories and specialists as possible throughout Europe.

“In Axonlab, we have gained a partner who shares our values and our commitment to quality. Together, we can provide even better support to dermatologists and (dermato)pathologists with our fully automated molecular diagnostic system and offer pa-tients real added value,” says Dermagnostix Chief Commercial Officer Tobias Rohde.

The expansion of the Axonlab range with the Dermagnostix portfolio applies to the following seven Axonlab countries: Austria, Croatia, Poland, Switzerland, Slovakia, Slovenia and the Czech Republic.